Physician profile
Ayman Aboud
NPI 1023364395
$3,038.23
in general payments reported to CMS, 2019-2025
27 companies · $368 in 2025
The $368 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $243 · 2021: $554 · 2022: $486 · 2023: $628 · 2024: $398 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $358.33 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Tris Pharma INC | $353.46 | 2019-2023 | Dyanavel Xr |
| Cranial Technologies, INC | $352.04 | 2019-2025 | Doc Band |
| Supernus Pharmaceuticals, INC. | $340.06 | 2023-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $319.45 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Takeda Pharmaceuticals U.S.A., INC. | $186.90 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $180.91 | 2019-2024 | |
| Abbvie INC. | $120.02 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $115.96 | 2025 | Daybue |
| Pfizer INC. | $114.55 | 2019-2025 | |
| Sanofi Pasteur INC. | $105.34 | 2019-2024 | |
| Corium, LLC | $79.04 | 2022-2023 | Azstarys |
| Sobi, INC | $74.90 | 2019-2021 | |
| Neurelis, INC. | $52.06 | 2021-2023 | Valtoco |
| Seqirus USA INC | $44.12 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $33.89 | 2024-2025 | Ycanth |
| Shire North American Group INC | $24.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.65 | 2025 | |
| Collegium Pharmaceutical, INC. | $22.15 | 2025 | Jornay Pm |
| Kyowa Kirin, INC. | $21.43 | 2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $19.97 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.25 | 2025 | Alvesco |
| Phadia US INC. | $16.96 | 2023 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $16.45 | 2023 | Evusheld |
| Biogen, INC. | $14.68 | 2021 | |
| Photonicare INC | $14.51 | 2024 | Otosight Middle Ear Scope |
| Mission Pharmacal Company | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Aboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.